<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20937790</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>238</EndPage><MedlinePgn>229-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.00855-10</ELocationID><Abstract><AbstractText>Dengue virus (DENV) causes disease globally, with an estimated 25 to 100 million new infections per year. At present, no effective vaccine is available, and treatment is supportive. In this study, we identified BP2109, a potent and selective small-molecule inhibitor of the DENV NS2B/NS3 protease, by a high-throughput screening assay using a recombinant protease complex consisting of the central hydrophilic portion of NS2B and the N terminus of the protease domain. BP2109 inhibited DENV (serotypes 1 to 4), but not Japanese encephalitis virus (JEV), replication and viral RNA synthesis without detectable cytotoxicity. The compound inhibited recombinant DENV-2 NS2B/NS3 protease with a 50% inhibitory concentration (IC(50)) of 15.43 &#xb1; 2.12 &#x3bc;M and reduced the reporter expression of the DENV-2 replicon with a 50% effective concentration (EC(50)) of 0.17 &#xb1; 0.01 &#x3bc;M. Sequencing analyses of several individual clones derived from BP2109-resistant DENV-2 RNAs revealed that two amino acid substitutions (R55K and E80K) are found in the region of NS2B, a cofactor of the NS2B/NS3 protease complex. The introduction of R55K and E80K double mutations into the dengue virus NS2B/NS3 protease and a dengue virus replicon construct conferred 10.3- and 73.8-fold resistance to BP2109, respectively. The E80K mutation was further determined to be the key mutation conferring dengue virus replicon resistance (61.3-fold) to BP2109, whereas the R55K mutation alone did not affect resistance to BP2109. Both the R55K and E80K mutations are located in the central hydrophilic portion of the NS2B cofactor, where extensive interactions with the NS3pro domain exist. Thus, our data provide evidence that BP2109 likely inhibits DENV by a novel mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chi-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes (NHRI), Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shiow-Ju</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Szu-Huei</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Ching-Len</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Chang-Huei</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Yu-Sheng</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Jyh-Haur</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chung-Pu</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Yueh</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20937790</ArticleId><ArticleId IdType="pmc">PMC3019636</ArticleId><ArticleId IdType="doi">10.1128/AAC.00855-10</ArticleId><ArticleId IdType="pii">AAC.00855-10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arakaki, T. L., N. X. Fang, D. P. Fairlie, P. R. Young, and J. L. Martin. 2002. Catalytically active Dengue virus NS3 protease forms aggregates that are separable by size exclusion chromatography. Protein Expr. Purif. 25:241-247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan, J. F., and R. J. Fletterick. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171:637-639.</Citation><ArticleIdList><ArticleId IdType="pubmed">2548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Beran, R. K., and A. M. Pyle. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 283:29929-29937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573085</ArticleId><ArticleId IdType="pubmed">18723512</ArticleId></ArticleIdList></Reference><Reference><Citation>Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.</Citation><ArticleIdList><ArticleId IdType="pubmed">11110665</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke, D. 2000. Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual. Cold Spring Harbor Laboratory Press, Plainview, NY.</Citation></Reference><Reference><Citation>Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.</Citation><ArticleIdList><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanprapaph, S., P. Saparpakorn, C. Sangma, P. Niyomrattanakit, S. Hannongbua, C. Angsuthanasombat, and G. Katzenmeier. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330:1237-1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, L. K., Y. L. Lin, C. L. Liao, C. G. Lin, Y. L. Huang, C. T. Yeh, S. C. Lai, J. T. Jan, and C. Chin. 1996. Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 223:79-88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8806542</ArticleId></ArticleIdList></Reference><Reference><Citation>Deas, T. S., I. Binduga-Gajewska, M. Tilgner, P. Ren, D. A. Stein, H. M. Moulton, P. L. Iversen, E. B. Kauffman, L. D. Kramer, and P. Y. Shi. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069577</ArticleId><ArticleId IdType="pubmed">15795246</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel, P., N. Schiering, A. D'Arcy, M. Renatus, M. Kroemer, S. P. Lim, Z. Yin, T. H. Keller, S. G. Vasudevan, and U. Hommel. 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13:372-373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout, B., M. Pethel, Y. M. Zhang, and C. J. Lai. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65:2467-2475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh, V. K., N. Muller, K. Judge, C. H. Luan, R. Padmanabhan, and K. H. Murthy. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13:257-264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbalenya, A. E., A. P. Donchenko, E. V. Koonin, and V. M. Blinov. 1989. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res. 17:3889-3897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC317867</ArticleId><ArticleId IdType="pubmed">2543956</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler, D., G. Kuno, and L. Markoff. 2007. Flaviviruses, p. 1153-1253. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed., vol. 1. Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Gubler, D. J. 1989. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig lecture. Am. J. Trop. Med. Hyg. 40:571-578.</Citation><ArticleIdList><ArticleId IdType="pubmed">2472746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman, M. G., and G. Kouri. 2004. Dengue diagnosis, advances and challenges. Int. J. Infect. Dis. 8:69-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">14732325</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman, M. G., and G. Kouri. 2002. Dengue: an update. Lancet Infect. Dis. 2:33-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11892494</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead, S. B. 1980. Dengue haemorrhagic fever&#x2014;a public health problem and a field for research. Bull. World Health Organ. 58:1-21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395896</ArticleId><ArticleId IdType="pubmed">6966540</ArticleId></ArticleIdList></Reference><Reference><Citation>Houng, H. H., D. Hritz, and N. Kanesa-Thasan. 2000. Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3&#x2032;-noncoding sequence. J. Virol. Methods 86:1-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10713370</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston, P. A., J. Phillips, T. Y. Shun, S. Shinde, J. S. Lazo, D. M. Huryn, M. C. Myers, B. I. Ratnikov, J. W. Smith, Y. Su, R. Dahl, N. D. Cosford, S. A. Shiryaev, and A. Y. Strongin. 2007. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev. Technol. 5:737-750.</Citation><ArticleIdList><ArticleId IdType="pubmed">18181690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai, C. Y., H. P. Hu, C. C. King, and W. K. Wang. 2008. Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J. Biomed Sci. 15:15-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">17768670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescar, J., D. Luo, T. Xu, A. Sampath, S. P. Lim, B. Canard, and S. G. Vasudevan. 2008. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target. Antiviral Res. 80:94-101.</Citation><ArticleIdList><ArticleId IdType="pubmed">18674567</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung, D., K. Schroder, H. White, N. X. Fang, M. J. Stoermer, G. Abbenante, J. L. Martin, P. R. Young, and D. P. Fairlie. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276:45762-45771.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581268</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen, P., E. De Clercq, and J. Neyts. 2008. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res. 78:9-25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114363</ArticleId><ArticleId IdType="pubmed">18313769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, Y. L., C. L. Liao, L. K. Chen, C. T. Yeh, C. I. Liu, S. H. Ma, Y. Y. Huang, Y. L. Huang, C. L. Kao, and C. C. King. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729-9737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, Y. L., C. C. Liu, H. Y. Lei, T. M. Yeh, Y. S. Lin, R. M. Chen, and H. S. Liu. 2000. Infection of five human liver cell lines by dengue-2 virus. J. Med. Virol. 60:425-431.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686026</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, D., T. Xu, C. Hunke, G. Gruber, S. G. Vasudevan, and J. Lescar. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82:173-183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224403</ArticleId><ArticleId IdType="pubmed">17942558</ArticleId></ArticleIdList></Reference><Reference><Citation>Melino, S., S. Fucito, A. Campagna, F. Wrubl, A. Gamarnik, D. O. Cicero, and M. Paci. 2006. The active essential CFNS3d protein complex. FEBS J. 273:3650-3662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16911516</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez-Arias, L. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 85:210-231.</Citation><ArticleIdList><ArticleId IdType="pubmed">19616029</ArticleId></ArticleIdList></Reference><Reference><Citation>Miroux, B., and J. E. Walker. 1996. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260:289-298.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757792</ArticleId></ArticleIdList></Reference><Reference><Citation>Monath, T. P. 2008. Treatment of yellow fever. Antiviral Res. 78:116-124.</Citation><ArticleIdList><ArticleId IdType="pubmed">18061688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller, N. H., N. Pattabiraman, C. Ansarah-Sobrinho, P. Viswanathan, T. C. Pierson, and R. Padmanabhan. 2008. Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob. Agents Chemother. 52:3385-3393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533463</ArticleId><ArticleId IdType="pubmed">18606844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, C. Y., F. Gu, W. Y. Phong, Y. L. Chen, S. P. Lim, A. Davidson, and S. G. Vasudevan. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76:222-231.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662475</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyomrattanakit, P., P. Winoyanuwattikun, S. Chanprapaph, C. Angsuthanasombat, S. Panyim, and G. Katzenmeier. 2004. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J. Virol. 78:13708-13716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533897</ArticleId><ArticleId IdType="pubmed">15564480</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble, C. G., Y. L. Chen, H. Dong, F. Gu, S. P. Lim, W. Schul, Q. Y. Wang, and P. Y. Shi. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res. 85:450-462.</Citation><ArticleIdList><ArticleId IdType="pubmed">20060421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro, F. P. 1989. Dengue in the Americas. 1980-1987. Epidemiol. Bull. 10:1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484241</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro, F. P., and S. J. Corber. 1997. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat. Q 50:161-169.</Citation><ArticleIdList><ArticleId IdType="pubmed">9477544</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig-Basagoiti, F., M. Tilgner, B. M. Forshey, S. M. Philpott, N. G. Espina, D. E. Wentworth, S. J. Goebel, P. S. Masters, B. Falgout, P. Ren, D. M. Ferguson, and P. Y. Shi. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1426921</ArticleId><ArticleId IdType="pubmed">16569847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice, C. M., E. M. Lenches, S. R. Eddy, S. J. Shin, R. L. Sheets, and J. H. Strauss. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229:726-733.</Citation><ArticleIdList><ArticleId IdType="pubmed">4023707</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampath, A., and R. Padmanabhan. 2009. Molecular targets for flavivirus drug discovery. Antiviral Res. 81:6-15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647018</ArticleId><ArticleId IdType="pubmed">18796313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1203683</ArticleId><ArticleId IdType="pubmed">2659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, V., A. Madejon, E. Vispo, P. Labarga, J. Garcia-Samaniego, L. Martin-Carbonero, J. Sheldon, M. Bottecchia, P. Tuma, and P. Barreiro. 2008. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs 13:1-19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18321145</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle, R. P., and B. Falgout. 1998. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72:624-632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109416</ArticleId><ArticleId IdType="pubmed">9420267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichapong, K., S. Pianwanit, W. Sippl, and S. Kokpol. 2010. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. J. Mol. Recognit. 23:283-300.</Citation><ArticleIdList><ArticleId IdType="pubmed">19693793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C. F., S. H. Wang, C. M. Sun, S. T. Hu, and W. J. Syu. 2003. Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins. J. Virol. Methods 114:45-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">14599678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, S. F., C. J. Lee, C. L. Liao, R. A. Dwek, N. Zitzmann, and Y. L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76:3596-3604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136089</ArticleId><ArticleId IdType="pubmed">11907199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, Z., S. J. Patel, W. L. Wang, W. L. Chan, K. R. Ranga Rao, G. Wang, X. Ngew, V. Patel, D. Beer, J. E. Knox, N. L. Ma, C. Ehrhardt, S. P. Lim, S. G. Vasudevan, and T. H. Keller. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16:40-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, Z., S. J. Patel, W. L. Wang, G. Wang, W. L. Chan, K. R. Rao, J. Alam, D. A. Jeyaraj, X. Ngew, V. Patel, D. Beer, S. P. Lim, S. G. Vasudevan, and T. H. Keller. 2006. Peptide inhibitors of Dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett. 16:36-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246553</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusof, R., S. Clum, M. Wetzel, H. M. Murthy, and R. Padmanabhan. 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 275:9963-9969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, G., F. Puig-Basagoiti, B. Zhang, M. Qing, L. Chen, K. W. Pankiewicz, K. Felczak, Z. Yuan, and P. Y. Shi. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242-252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388927</ArticleId><ArticleId IdType="pubmed">19062063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>